Literature DB >> 4603014

Studies of the human lymphocyte receptor for heat-aggregated or antigen-complexed immunoglobulin.

H B Dickler.   

Abstract

The lymphocyte receptor for complexed immunoglobulin was shown not to bind heat-aggregated human serum albumin, bovine serum albumin, transferrin, F(ab')(2), reduced and alkylated Ig, and mildly oxidized Ig, which indicated that the receptor is specific for a site dependent on disulfide bond(s) on the Fc portion of complexed Ig. Inhibition experiments provided evidence that the same receptor binds both heat-aggregated Ig and antigen-antibody complexes. Lymphocytes treated with pronase were no longer able to bind Ig complexes, which suggested that the receptor is a protein or glycoprotein. Additional evidence was obtained that lymphocyte surface Ig and the receptor for complexed Ig are distinct since the former could be capped without affecting the distribution of the latter, and surface Ig was not detectable after trypsinization of lymphocytes, whereas the binding of Ig complexes was unaffected by such treatment. Incubation of lymphocytes which had bound Ig complexes in tissue culture medium at 37 degrees C revealed that the complexes remained on the surface membrane for several hours, and that only a minority of lymphocytes binding complexes showed cap formation. Lymphocytes which had heat-aggregated IgG specifically bound to their receptors for complexed Ig were markedly inhibited in their ability to mediate antibody-dependent cytotoxicity, thus providing strong evidence for the necessity of the receptor in this immune activity. Titration of this inhibition with varying amounts of complexes revealed distinct plateaus in the dose-response curve. This suggested that there may be more than one kind of receptor and/or different populations of lymphocytes which bear the receptor.

Entities:  

Mesh:

Substances:

Year:  1974        PMID: 4603014      PMCID: PMC2139583          DOI: 10.1084/jem.140.2.508

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  23 in total

1.  T cells can bind antigen via cytophilic IgM antibody made by B cells.

Authors:  S R Webb; M D Cooper
Journal:  J Immunol       Date:  1973-07       Impact factor: 5.422

2.  Specificiy of lymphocyte-mediated cytotoxicity induced by in vitro antibody-coated target cells.

Authors:  G Möller; S E Svehag
Journal:  Cell Immunol       Date:  1972-05       Impact factor: 4.868

3.  A receptor for Fc on mouse B-lymphocytes.

Authors:  F Paraskevas; S T Lee; K B Orr; L G Israels
Journal:  J Immunol       Date:  1972-05       Impact factor: 5.422

4.  Cell interactions in the immune response in vitro. V. Specific collaboration via complexes of antigen and thymus-derived cell immunoglobulin.

Authors:  M Feldmann
Journal:  J Exp Med       Date:  1972-10-01       Impact factor: 14.307

5.  The biologic significance of Fc receptor on mouse B-lymphocytes.

Authors:  F Paraskevas; K B Orr; E D Anderson; S T Lee; L G Israels
Journal:  J Immunol       Date:  1972-06       Impact factor: 5.422

6.  Isolation and partial characterization of lymphocyte surface immunoglobulins.

Authors:  J J Marchalonis; R E Cone; J L Atwell
Journal:  J Exp Med       Date:  1972-04-01       Impact factor: 14.307

7.  In vitro adherence of soluble immune complexes to macrophages.

Authors:  W P Arend; M Mannik
Journal:  J Exp Med       Date:  1972-09-01       Impact factor: 14.307

8.  Interaction of aggregated -globulin with B lymphocytes.

Authors:  H B Dickler; H G Kunkel
Journal:  J Exp Med       Date:  1972-07-01       Impact factor: 14.307

9.  A receptor for antibody on B lymphocytes. I. Method of detection and functional significance.

Authors:  A Basten; J F Miller; J Sprent; J Pye
Journal:  J Exp Med       Date:  1972-03-01       Impact factor: 14.307

10.  A receptor for antibody on B lymphocytes. II. Immunochemical and electron microscopy characteristics.

Authors:  A Basten; N L Warner; T Mandel
Journal:  J Exp Med       Date:  1972-03-01       Impact factor: 14.307

View more
  72 in total

1.  Immunocompetent cells from the lower respiratory tract of normal human lungs.

Authors:  R P Daniele; M D Altose; D T Rowlands
Journal:  J Clin Invest       Date:  1975-10       Impact factor: 14.808

2.  Human lymphocyte subpopulations effect of epinephrine.

Authors:  D T Yu; P J Clements
Journal:  Clin Exp Immunol       Date:  1976-09       Impact factor: 4.330

3.  Heterogeneity of human lymphocyte Fc receptors. II. Relationship to antibody-dependent, cell-mediated cytotoxicity.

Authors:  B J Gormus; M Woodson; M E Kaplan
Journal:  Clin Exp Immunol       Date:  1978-11       Impact factor: 4.330

4.  Interaction of lymphocytes with lipid bilayer membranes: a model for lymphocyte-mediated lysis of target cells.

Authors:  P Henkart; R Blumenthal
Journal:  Proc Natl Acad Sci U S A       Date:  1975-07       Impact factor: 11.205

5.  Editorial: Cell surface receptors on lymphocytes.

Authors:  R K Chandra
Journal:  Indian J Pediatr       Date:  1975-08       Impact factor: 1.967

6.  Increased EA-rosette formation by lymphocytes from patients with rheumatoid arthritis.

Authors:  R K Sharpin; J D Wilson
Journal:  Clin Exp Immunol       Date:  1977-08       Impact factor: 4.330

7.  Effect of ageing on surface IgG of human peripheral lymphocytes.

Authors:  C Zanussi; C Rugarli; B Perussia; R S Smeraldi
Journal:  Experientia       Date:  1977-06-15

8.  Studies on the nature of EA binding by lymphocytes from rheumatoid arthritis patients.

Authors:  R K Sharpin; J D Wilson
Journal:  Clin Exp Immunol       Date:  1977-08       Impact factor: 4.330

9.  Detection of immune complexes. The use of radioimmunoassays with Clq and monoclonal rheumatoid factor.

Authors:  A Gabriel; V Agnello
Journal:  J Clin Invest       Date:  1977-05       Impact factor: 14.808

10.  Localization of T and B cells and alpha fetoprotein in hepatic biopsies from patients with liver disease.

Authors:  G Husby; R G Strickland; J L Caldwell; R C Williams
Journal:  J Clin Invest       Date:  1975-11       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.